Beyond PSA—Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?
Medical Sciences · 07.05.2026 · 14 (2) · 243
DOI: 10.3390/medsci14020243 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Sciences, online erschienen am 07.05.2026. Verfasst von Marius Ivănuță und 6 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Inflammation. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prostate-specific antigen (PSA) remains the primary biomarker for prostate cancer detection; however, its limited specificity leads to unnecessary biopsies. Systemic inflammatory indices derived from routine blood tests have been proposed as potential adjunctive diagnostic tools. This study aimed to evaluate the diagnostic performance of these indices in patients undergoing prostate biopsy for suspected prostate cancer.
Methods
A retrospective observational study was conducted, including 307 patients who underwent transrectal ultrasound-guided prostate biopsy for elevated PSA between January 2021 and January 2023. Patients were classified as benign prostatic hyperplasia (BPH) or prostate cancer (PCa) based on histopathological findings. Inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), systemic immune–inflammation index (SII), Systemic Inflammation Response Index (SIRI), and aggregate index of systemic inflammation (AISI), were calculated. Logistic regression and receiver operating characteristic (ROC) analyses were performed to assess diagnostic performance.
Results
PCa was diagnosed in 65.1% of patients. Several inflammatory indices were significantly higher in the PCa group. Among them, AISI showed diagnostic performance comparable to PSA. The integration of inflammatory indices into multivariable models improved predictive accuracy, with the combined model demonstrating the highest discriminative ability. In contrast, these markers showed limited capacity in distinguishing tumour aggressiveness.
Conclusions
Systemic inflammatory indices are associated with prostate cancer presence and may enhance diagnostic performance when used alongside PSA. However, their role remains complementary, as they provide limited value in risk stratification and should not be considered standalone diagnostic tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- Department of Urology, "Dr. C.I. Parhon" Clinical Hospital, 700503 Iasi, Romania.
- Emergency Care Department, "Sf. Spiridon" County University Emergency Hospital, 700111 Iasi, Romania.
- Department of Urology, "Sf. Ioan cel Nou" County Emergency Hospital, 720033 Suceava, Romania.
ORCID-Profile: Marius Ivănuță, Abdallah Shurrab, Dragoș Puia, Mihaela Corlade-Andrei
Zitieren
APA
Ivănuță, M., Shurrab, A., Puia, D., Ivănuță, A. M., Corlade-Andrei, M., Stoican, N., & Pricop, C. (2026). Beyond PSA—Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?. Medical Sciences, 14(2), 243. https://doi.org/10.3390/medsci14020243
Vancouver
Ivănuță M, Shurrab A, Puia D, Ivănuță AM, Corlade-Andrei M, Stoican N, et al. Beyond PSA—Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?. Medical Sciences. 2026;14(2):243. doi:10.3390/medsci14020243
BibTeX
@article{Ivnu2026,
author = {Ivănuță, Marius and Shurrab, Abdallah and Puia, Dragoș and Ivănuță, Ana-Maria and Corlade-Andrei, Mihaela and Stoican, Nicolae and Pricop, Cătălin},
title = {Beyond PSA—Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {243},
doi = {10.3390/medsci14020243}
}
EUVIMED